Dr. Reddy’s Laboratories launches Tadalafil Tablets USP in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY),
along with its subsidiaries together referred to as “Dr. Reddy’s”) today
announced the launch of Tadalafil Tablets USP, a therapeutic equivalent
generic version of Adcirca (tadalafil) Tablets in the United States
market, approved by the U.S. Food and Drug Administration (USFDA).

The Adcirca brand and generic had U.S. sales of approximately $490
million MAT for the most recent twelve months ending in November 2018
according to IMS Health*.

Dr. Reddy’s Tadalafil Tablets are available in 20 mg with 60 count
bottle size.

Adcirca is a trademark of Eli Lilly and Company.

*IMS National Sales Perspective: Retail and Non-Retail MAT November 2018
RDY-0219-234

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy’s operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may”, “will”, “should”, “expects”,
“plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”,
“potential”, or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss
events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.

The company assumes no obligation to update any information contained
herein

Contacts

INVESTOR RELATIONS
AMIT AGARWAL
amita@drreddys.com
(Ph:
+91-40-49002135)

MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
(Ph:
+91-40- 49002121)